Stratos Wealth Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $686K | Buy |
5,372
+482
| +10% | +$60.2K | 0.01% | 943 |
|
|
2025
Q4 | $596K | Buy |
4,890
+1,185
| +32% | +$136K | 0.01% | 973 |
|
|
2025
Q3 | $371K | Sell |
3,705
-506
| -12% | -$45.6K | ﹤0.01% | 1150 |
|
|
2025
Q2 | $349K | Buy |
4,211
+39
| +0.9% | +$3.11K | ﹤0.01% | 1077 |
|
|
2025
Q1 | $338K | Sell |
4,172
-3,596
| -46% | -$321K | 0.01% | 1034 |
|
|
2024
Q4 | $700K | Sell |
7,768
-1,061
| -12% | -$103K | 0.01% | 815 |
|
|
2024
Q3 | $872K | Sell |
8,829
-1,011
| -10% | -$99.3K | 0.01% | 737 |
|
|
2024
Q2 | $912K | Sell |
9,840
-2,829
| -22% | -$254K | 0.01% | 684 |
|
|
2024
Q1 | $1.2M | Sell |
12,669
-1,293
| -9% | -$120K | 0.02% | 587 |
|
|
2023
Q4 | $1.25M | Sell |
13,962
-616
| -4% | -$45.7K | 0.02% | 545 |
|
|
2023
Q3 | $1.06M | Sell |
14,578
-617
| -4% | -$49.3K | 0.02% | 552 |
|
|
2023
Q2 | $1.26M | Sell |
15,195
-424
| -3% | -$35.5K | 0.03% | 470 |
|
|
2023
Q1 | $1.19M | Sell |
15,619
-766
| -5% | -$63.6K | 0.03% | 436 |
|
|
2022
Q4 | $1.36M | Sell |
16,385
-597
| -4% | -$48.3K | 0.03% | 428 |
|
|
2022
Q3 | $1.35M | Sell |
16,982
-1,435
| -8% | -$121K | 0.04% | 404 |
|
|
2022
Q2 | $1.37M | Sell |
18,417
-15,154
| -45% | -$1.14M | 0.03% | 410 |
|
|
2022
Q1 | $3.02M | Buy |
33,571
+17,524
| +109% | +$1.62M | 0.07% | 268 |
|
|
2021
Q4 | $1.8M | Sell |
16,047
-466
| -3% | -$56.2K | 0.04% | 383 |
|
|
2021
Q3 | $2.08M | Buy |
16,513
+366
| +2% | +$47.1K | 0.05% | 308 |
|
|
2021
Q2 | $2.19M | Buy |
16,147
+177
| +1% | +$23.3K | 0.05% | 312 |
|
|
2021
Q1 | $2.17M | Buy |
15,970
+2,231
| +16% | +$334K | 0.06% | 281 |
|
|
2020
Q4 | $1.93M | Buy |
13,739
+493
| +4% | +$63.1K | 0.06% | 273 |
|
|
2020
Q3 | $1.48M | Sell |
13,246
-1,224
| -8% | -$137K | 0.05% | 307 |
|
|
2020
Q2 | $1.62M | Buy |
14,470
+1,288
| +10% | +$127K | 0.06% | 293 |
|
|
2020
Q1 | $1.02M | Sell |
13,182
-250
| -2% | -$22.1K | 0.05% | 322 |
|
|
2019
Q4 | $1.28M | Sell |
13,432
-1,097
| -8% | -$94.9K | 0.05% | 326 |
|
|
2019
Q3 | $1.11M | Sell |
14,529
-1,582
| -10% | -$131K | 0.05% | 345 |
|
|
2019
Q2 | $1.41M | Sell |
16,111
-443
| -3% | -$37.8K | 0.06% | 283 |
|
|
2019
Q1 | $1.5M | Buy |
16,554
+543
| +3% | +$46.2K | 0.07% | 287 |
|
|
2018
Q4 | $1.15M | Buy |
16,011
+73
| +0.5% | +$5.88K | 0.06% | 303 |
|
|
2018
Q3 | $1.53M | Buy |
15,938
+1,364
| +9% | +$132K | 0.07% | 259 |
|
|
2018
Q2 | $1.39M | Buy |
14,574
+824
| +6% | +$75.7K | 0.06% | 298 |
|
|
2018
Q1 | $1.21M | Buy |
13,750
+921
| +7% | +$84.1K | 0.05% | 326 |
|
|
2017
Q4 | $1.09M | Buy |
12,829
+35
| +0.3% | +$2.93K | 0.05% | 334 |
|
|
2017
Q3 | $1.11M | Buy |
12,794
+1,266
| +11% | +$101K | 0.05% | 312 |
|
|
2017
Q2 | $890K | Buy |
11,528
+3,269
| +40% | +$232K | 0.05% | 314 |
|
|
2017
Q1 | $573K | Buy |
8,259
+1,282
| +18% | +$86.1K | 0.03% | 390 |
|
|
2016
Q4 | $413K | Buy |
6,977
+382
| +6% | +$23.6K | 0.03% | 436 |
|
|
2016
Q3 | $437K | Buy |
6,595
+45
| +0.7% | +$2.78K | 0.03% | 391 |
|
|
2016
Q2 | $354K | Hold |
6,550
| – | – | 0.03% | 408 |
|
|
2016
Q1 | $338K | Sell |
6,550
-513
| -7% | -$26.6K | 0.03% | 384 |
|
|
2015
Q4 | $496K | Sell |
7,063
-6,375
| -47% | -$435K | 0.04% | 306 |
|
|
2015
Q3 | $837K | Buy |
13,438
+9,325
| +227% | +$735K | 0.11% | 171 |
|
|
2015
Q2 | $346K | Buy |
+4,113
| New | +$320K | 0.04% | 330 |
|
Other funds holding XBI
Stratos Wealth Partners's XBI Position: Q1 2026 in Review
Stratos Wealth Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 9.9% in Q1 2026, buying an estimated $60.2K and bringing the position to 5,372 shares worth $686K. The position accounts for 0.01% of the portfolio, ranked #943.
Stratos Wealth Partners first reported a position in XBI in Q2 2015 and has held it in 44 quarters since. The position peaked at $3.02M in Q1 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Stratos Wealth Partners held 5,372 shares of State Street SPDR S&P Biotech ETF worth $686K as of Q1 2026.
- Stratos Wealth Partners bought 482 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $60.2K.
- State Street SPDR S&P Biotech ETF made up 0.01% of Stratos Wealth Partners's portfolio in Q1 2026, its #943 holding.
- Stratos Wealth Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and has held it in 44 quarters since.
- Stratos Wealth Partners's State Street SPDR S&P Biotech ETF position peaked at $3.02M in Q1 2022.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.